Resources
10 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 11/11/2021 (updated 4/3/2024)
This session presented resources and elements to consider when planning to collaborate with a local jail to establish pre- and post-release programing and coordination of care and services for individuals with SUD. A real-world example was presented by an RCORP grantee showcasing its First Day Forward Program.
Posted 11/11/2021 (updated 4/3/2024)
JBS’s Robert Childs discussed the key concepts of harm reduction and evidence-based harm reduction interventions that grantees can implement to reduce overdose in their rural communities. Staff from Arkansas Behavioral Health Integration Network shared lessons learned from their RCORP-Planning grant in gaining buy-in for harm reduction concepts and planning for harm reduction services in rural Arkansas.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 6/12/2020 (updated 3/28/2024)
The HHS Office of the Assistant Secretary for Health (OASH) Regional Health Administrators presented a webinar series highlighting resources, policies, and assistance for developing and expanding SSPs in diverse settings and in different communities across the country, the three webinars were held in 2019.
Posted 11/20/2023 (updated 3/28/2024)
The U.S. Food and Drug Administration cleared the use of Alltest Fentanyl Urine Test Cassette, which is the first over-the-counter test for the preliminary detection of fentanyl in urine. The test works by placing three drops of fresh urine onto a cassette containing a fentanyl test strip. After 5 minutes the test result will appear as colored lines. Although the test does not distinguish between certain drugs and medications.
Posted 12/13/2022 (updated 3/27/2024)
The U.S. Department of Health and Human Services (HHS) announced the progress made since the release of the Overdose Prevention Strategy (Strategy) last fall. The new data shows treatment capacity, lives saved from overdose, and commitments to long-term recovery supports, as well as a hopeful trend of a decrease in overdose deaths.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 6/14/2022 (updated 3/27/2024)
On Wednesday, the U.S. Department of Health & Human Services announced nearly $15 million awarded to rural communities to continue addressing misuse of illegal and prescription drugs known as psychostimulants. These awards are part of the Rural Communities Opioid Response Program (RCORP), a multi-year initiative with $400 million invested since its start in 2018.
Posted 3/22/2022 (updated 3/27/2024)
Yesterday, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), is announcing two grant programs totaling $25.6 million that will expand access to medication-assisted treatment for opioid use disorder and prevent the misuse of prescription drugs. By reducing barriers to accessing the most effective, evidenced-based treatments, this funding reflects the priorities of HHS' Overdose Prevention Strategy, as well as its new initiative to strengthen the nation's mental health and crisis care systems.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.